Lei Xiaoming

Company snapshot

Lei Xiaoming is a pharma organization headquartered in CN. Primary therapeutic focus areas include Cystic Adenomatoid Malformation of Lung, Congenital. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lei Xiaoming. Not investment advice.

• What is Lei Xiaoming?

  Lei Xiaoming is a pharma organization headquartered in CN. Primary therapeutic focus areas include Cystic Adenomatoid Malformation of Lung, Congenital. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clini

• Is Lei Xiaoming publicly traded?

  Lei Xiaoming appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Lei Xiaoming develop or market?

  We link 1 drug profile(s) where Lei Xiaoming is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lei-xiaoming#company-drugs.

• What are the latest developments for Lei Xiaoming?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lei Xiaoming focus on?

  Lei Xiaoming focuses on Cystic Adenomatoid Malformation of Lung, Congenital based on our analysis of their pipeline programs and drug development activities.